<DOC>
	<DOCNO>NCT00524706</DOCNO>
	<brief_summary>Introduction : S-1 promising drug could replace 5-fluorouracil plus l-leucovorin ( 5-FU/l-LV ) treatment advanced colorectal cancer . Phase I/II study S-1 plus Oxaliplatin ( SOX ) demonstrate promising activity acceptable toxicity first-line chemotherapy patient untreated metastatic colorectal cancer S-1 show equivalent possibility 5-FU/l-LV . On hand , phase I/II study S-1 plus oral Leucovorin ( S-1/LV ) demonstrate regimen enhance efficacy comparison S-1 alone . From result , expect S-1/LV plus Oxaliplatin ( SOL ) would effective SOX . Therefore , phase I/II study SOL combination therapy plan . Purpose A dose-finding study S-1/LV plus Oxaliplatin ( SOL ) plan determine recommend dose ( RD ) , assess response rate ( RR ) patient untreated metastatic colorectal cancer . The primary endpoint phase I portion determination RD SOL , safety . The phase II portion study aim assess RR SOL .</brief_summary>
	<brief_title>Phase I/II Study SOL Untreated Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Written inform consent . Adequate oral intake . Histologically prove adenocarcinoma ( colorectal cancer ) . Unresectable , recurrent advance colorectal cancer . At least 4 week since prior major surgery Age : 20 74 enrollment . Performance Status ( Eastern Cooperative Oncology Group [ ECOG ] scale ) : 0 2 . No prior treatment ( ex . radiation therapy , chemotherapy , hormonal therapy ) advance disease . Patients receive adjuvant chemotherapy 180 day enrollment allow receive S1 Oxaliplatin contain treatment shall exclude . Proved presence measurable lesion within 30 day enrollment . Patients follow function bone marrow , liver kidney base laboratory value measure within 15 day enrollment . Hemoglobin &gt; _ 9.0g/dL WBC : LLN 12,000/mm3 Absolute granulocyte count &gt; _ 1,500/mm3 Platelets &gt; _ 100,000/mm3 Total Bilirubin &lt; _ 1.5mg/dL AST ( GOT ) ALT ( GPT ) &lt; _ 100U/L ALP &lt; _ 600U/L Creatinine &lt; _ 1.0mg/dl Expected survive 90 day enrollment . Patients receive S1 Oxaliplatin neoadjuvant adjuvant chemotherapy enrollment . Contraindication S1 , serious hypersensitivity oral Leucovorin . No concurrent investigational therapy . Patients receive blood transfusion hematogenesis stimulate agent ( ex . GranulocyteColony Stimulating Factor ) . Serious drug hypersensitivity . Prior history peripheral neuropathy . Marked infection inflammation ( ex . patient fever 38.0 degree high ) . Poorlycontrolled diabetes , hypertension hypercalcemia . Severe ( inpatient care need ) arrhythmia , heart disease history . Severe ( inpatient care need ) lung disease ( ex . interstitial pneumonia pulmonary fibrosis ) . Psychiatric disorder require receive treatment antipsychotic drug . Fresh bleed gastrointestinal tract . Requiring drainage massive ascites , pleural effusion retention pericardial fluid . Extensive bone metastasis . Clinically suspicious brain metastasis brain metastasis . Diarrhea ( watery diarrhea ) . Simultaneously active double cancer . Pregnancy nurse female patient possibility ( intent ) bear baby . Male patient intent impregnate . Other patient evaluate inadequate participate study ( sub ) investigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>S-1</keyword>
	<keyword>oral fluoropyrimidine</keyword>
	<keyword>tegafur</keyword>
	<keyword>Gimeracil</keyword>
	<keyword>Oteracil Potassium</keyword>
	<keyword>Leucovorin</keyword>
	<keyword>Calcium Folinate</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>L-OHP</keyword>
	<keyword>colorectal cancer</keyword>
</DOC>